company background image
RQE1 logo

ReNeuron Group DB:RQE1 Stock Report

Last Price

€0.034

Market Cap

€2.2m

7D

0%

1Y

-62.2%

Updated

04 May, 2024

Data

Company Financials

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

RQE1 Stock Overview

Researches, develops, and commercializes cell-based therapies in the United Kingdom. More details

RQE1 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ReNeuron Group plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ReNeuron Group
Historical stock prices
Current Share PriceUK£0.034
52 Week HighUK£0.13
52 Week LowUK£0.001
Beta0.69
11 Month Change0%
3 Month Change-11.69%
1 Year Change-62.22%
33 Year Change-97.96%
5 Year Change-98.86%
Change since IPO-99.92%

Recent News & Updates

Recent updates

Shareholder Returns

RQE1DE BiotechsDE Market
7D0%-0.7%-0.02%
1Y-62.2%-17.2%8.2%

Return vs Industry: RQE1 underperformed the German Biotechs industry which returned -22.4% over the past year.

Return vs Market: RQE1 underperformed the German Market which returned 2% over the past year.

Price Volatility

Is RQE1's price volatile compared to industry and market?
RQE1 volatility
RQE1 Average Weekly Movementn/a
Biotechs Industry Average Movement6.5%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.3%

Stable Share Price: RQE1's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine RQE1's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199726n/awww.reneuron.com

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells.

ReNeuron Group plc Fundamentals Summary

How do ReNeuron Group's earnings and revenue compare to its market cap?
RQE1 fundamental statistics
Market cap€2.25m
Earnings (TTM)-€5.91m
Revenue (TTM)€290.24k

7.7x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RQE1 income statement (TTM)
RevenueUK£249.00k
Cost of RevenueUK£3.65m
Gross Profit-UK£3.40m
Other ExpensesUK£1.67m
Earnings-UK£5.07m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

May 30, 2024

Earnings per share (EPS)-0.089
Gross Margin-1,367.47%
Net Profit Margin-2,037.35%
Debt/Equity Ratio0%

How did RQE1 perform over the long term?

See historical performance and comparison